Enkhtsetseg Purev MD

PubMed

• Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a Phase II study.
  Jason R Westin, Tycel J Phillips, Amitkumar Mehta, Marc S Hoffmann, Eva Gonzalez-Barca
  Blood Advances. 2025-02-05
• Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogen...
  Phuong Vo, Ramaprasad Srinivasan, Enkhtsetseg Purev, Emily McDuffee, Tatyana Worthy
  Bone Marrow Transplantation. 2024-12-01
• Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy.
  Meryl Colton, Enkhtsetseg Purev, Bradley Haverkos, Steven Bair, Jagar Jasem
  Clinical Lymphoma, Myeloma & Leukemia. 2024-11-01

Journal Articles

• Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Patients with Acute Myeloid Leukemia  
  Daniel A Pollyea, Jonathan A Gutman, Enkhtsetseg Purev, Clayton Smith, Nature
• Article Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells  
  Natalie J Serkova, Daniel A Pollyea, Enkhtsetseg Purev, ScienceDirect

Abstracts/Posters

• Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide ...
  Enkhtsetseg Purev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy
  Enkhtsetseg Purev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
  Enkhtsetseg Purev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory ...
  Enkhtsetseg Purev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Re...
  Enkhtsetseg Purev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all